公开(公告)号：US20220267348A1

公开(公告)日：2022-08-25

申请号：US17628976

申请日：2020-07-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Saleem Ahmad ,  Ling Li ,  Hong Wu ,  John Hynes

IPC: C07D495/04 ,  C07D513/04

Abstract: Disclosed are compounds of Formula (I) [INSERT CHEMICAL STRUCTURE HERE] (I) or a salt or prodrug thereof, wherein: X is CR4 or N; and R1, R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

公开(公告)号：US10023562B2

公开(公告)日：2018-07-17

申请号：US15480682

申请日：2017-04-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Rajeev S. Bhide ,  John V. Duncia ,  John Hynes ,  Satheesh K. Nair ,  William J. Pitts ,  Sreekantha R. Kumar ,  Daniel S. Gardner ,  Natesan Murugesan ,  Venkatram Reddy Paidi ,  Joseph B. Santella ,  Ramesh Sistla ,  Hong Wu

IPC: C07D401/12 ,  C07D407/14 ,  C07D405/12 ,  C07D213/74 ,  C07D405/14 ,  C07D401/14 ,  C07D417/14

Abstract: Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.

公开(公告)号：US20170210730A1

公开(公告)日：2017-07-27

申请号：US15480682

申请日：2017-04-06

Applicant: Bristol-Myers Squibb Company

Inventor： Rajeev S. Bhide ,  John V. Duncia ,  John Hynes ,  Satheesh K. Nair ,  William J. Pitts ,  Sreekantha R. Kumar ,  Daniel S. Gardner ,  Natesan Murugesan ,  Venkatram Reddy Paidi ,  Joseph B. Santella ,  Ramesh Sistla ,  Hong Wu

IPC: C07D407/14 ,  C07D213/74 ,  C07D417/14 ,  C07D405/14 ,  C07D401/14 ,  C07D405/12 ,  C07D401/12

CPC classification number: C07D407/14 ,  C07D213/74 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/14

Abstract: Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.

公开(公告)号：US09546153B2

公开(公告)日：2017-01-17

申请号：US14441698

申请日：2013-11-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Rajeev S. Bhide ,  John V. Duncia ,  John Hynes ,  Satheesh K. Nair ,  William J. Pitts ,  Sreekantha R. Kumar ,  Daniel S. Gardner ,  Natesan Murugesan ,  Venkatram Reddy Paidi ,  Joseph B. Santella ,  Ramesh Sistla ,  Hong Wu

IPC: C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04 ,  C07D513/04 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

Abstract: Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a bicyclic heterocycle, and R1, R3, R4, R5 and R6 are as defined herein, that are useful as kinase modulators, including IRAK-4 modulation.

Abstract translation: 具有下式（I）的化合物或其立体异构体或其药学上可接受的盐，其中R 2是双环杂环，并且R 1，R 3，R 4，R 5和R 6如本文所定义，其可用作激酶调节剂，包括IRAK -4调制。

公开(公告)号：US08987311B2

公开(公告)日：2015-03-24

申请号：US14371281

申请日：2013-01-11

Applicant: Bristol-Myers Squibb Company

Inventor： Dharmpal S. Dodd ,  Christopher P. Mussari ,  Rajeev S. Bhide ,  Satheesh Kesavan Nair ,  Venkatram Reddy Paidi ,  Sreekantha Ratna Kumar ,  Abhisek Banerjee ,  Ramesh Sistla ,  William J. Pitts ,  John Hynes

IPC: C07D401/04 ,  A61K31/44 ,  C07D471/10 ,  C07D417/14

CPC classification number: C07D471/10 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: Compounds having the following formula: (I) wherein: A is an optionally substituted triazole, or a stereoisomer or a pharmaceutically-acceptable salt thereof, are useful as kinase modulators, including IRAK-4 modulation.

Abstract translation: 具有下式的化合物：（I）其中：A是任选取代的三唑或其立体异构体或其药学上可接受的盐，可用作激酶调节剂，包括IRAK-4调节。

公开(公告)号：US20220259205A1

公开(公告)日：2022-08-18

申请号：US17627915

申请日：2020-07-16

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Satheesh Kesavan Nair ,  Venkatram Reddy Paidi ,  Kandhasamy Sarkunam ,  Ramesh Kumar Sistla ,  John Hynes ,  Natesan Murugesan

IPC: C07D471/04 ,  C07D471/14 ,  C07D491/048

Abstract: Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X1 and X2 are independently C or N, provided that zero or one of X1 and X2 is N; Ring A represented by the structure is: or; and Q, R1, R2, R3, R4, R6, and p are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

公开(公告)号：US20200062777A1

公开(公告)日：2020-02-27

申请号：US16612478

申请日：2018-05-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Saleem AHMAD ,  Ling Li ,  Lidet A. Negash ,  John Hynes

IPC: C07D495/04 ,  C07D409/12

Abstract: Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CR4 or N; Y is CR5 or N; provided that only one of X and Y is N; (R1) is: or; wherein R1, R1a, R1b, R1c, R2, and R3 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

公开(公告)号：US10294229B2

公开(公告)日：2019-05-21

申请号：US15738362

申请日：2016-06-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Daniel S. Gardner ,  Joseph B. Santella ,  Venkatram Reddy Paidi ,  Hong Wu ,  John V. Duncia ,  Satheesh Kesavan Nair ,  John Hynes ,  Xiao Zhu

IPC: A61K31/437 ,  A61K31/519 ,  A61P29/00 ,  C07D487/04 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein HET is a heteroaryl selected from pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3 d]pyrimidinyl, pyrazolo[3,4 b]pyridinyl, pyrazolo[3,4 d]pyrimidinyl, imidazolo[4,5 b]pyridinyl, and imidazolo[4,5 d]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a nitrogen ring atom in said heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; A is pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxadiazolyl or dihydroisoxazolyl, each substituted with zero or 1 Ra; and R3, Ra, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

公开(公告)号：US20180072712A1

公开(公告)日：2018-03-15

申请号：US15818826

申请日：2017-11-21

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Venkatram Reddy Paidi ,  Sreekantha Ratna Kumar ,  Abhisek Banerjee ,  Ramesh Sistla ,  Satheesh Kesavan Nair ,  William J. Pitts ,  John Hynes

IPC: C07D417/14 ,  C07D487/04 ,  C07D471/04 ,  C07D413/14 ,  C07D417/04 ,  C07D413/04

CPC classification number: C07D417/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

Abstract: Compounds having the following formula: or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R7, are useful as kinase modulators, including IRAK-4 modulation.

公开(公告)号：US09242975B2

公开(公告)日：2016-01-26

申请号：US14371456

申请日：2013-01-11

Applicant: Bristol-Myers Squibb Company

Inventor： Venkatram Reddy Paidi ,  Sreekantha Ratna Kumar ,  Abhisek Banerjee ,  Ramesh Sistla ,  Satheesh Kesavan Nair ,  William J. Pitts ,  John Hynes

IPC: C07D417/14 ,  C07D413/14 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04

CPC classification number: C07D417/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04

Abstract: Compounds having the following formula: wherein A is, or; and X is N or C—R7, or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, are useful as kinase modulators, including IRAK-4 modulation.

Abstract translation: 具有下式的化合物：其中A是或; 并且X是N或C-R7，或其对映体，非对映体或其药学上可接受的盐，可用作激酶调节剂，包括IRAK-4调节。